Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Selexipag 1600 μg Single Tablet vs 8x200 μg Tablets
NCT02206295Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of selexipag in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Area under the plasma concentration-time curve at 23 days and Maximum plasma concentration at steady state at 23 days. Started Sep 2012; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02206295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206295.